Aadi Bioscience Inc. (AADI) Financial Statements (2025 and earlier)

Company Profile

Business Address 17383 SUNSET AVENUE
PACIFIC PALISADES, CA 90272
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:108,800172,600148,98942,60538,52562,614
Cash and cash equivalents62,88839,019148,98942,60538,52562,614
Short-term investments45,957133,541    
Other undisclosed cash, cash equivalents, and short-term investments(45)40    
Receivables5,4881,862    
Inventory, net of allowances, customer advances and progress billings6,4271,861    
Inventory6,4271,861    
Prepaid expense    510311754
Other current assets    1,604735616
Other undisclosed current assets3,8713,7062,283   
Total current assets:124,586180,029151,27244,71939,57063,984
Noncurrent Assets
Operating lease, right-of-use asset1,1691,52255764162
Property, plant and equipment4,8025085712216498
Intangible assets, net (including goodwill)   3,811   
Intangible assets, net (excluding goodwill)   3,811   
Deposits noncurrent assets    204041
Other noncurrent assets1,8662,1782,213   
Total noncurrent assets:7,8374,2086,638206366139
TOTAL ASSETS:132,423184,237157,91044,92539,93764,123
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:20,20418,44114,8841,7993,2315,457
Employee-related liabilities 4777331,968
Accounts payable5,8983,5196,439523440596
Accrued liabilities14,30614,9228,445471360661
Other undisclosed accounts payable and accrued liabilities    3281,6982,232
Debt     103 
Due to related parties 258   
Other undisclosed current liabilities6,19139413167  
Total current liabilities:26,39518,83515,2731,8673,3345,457
Noncurrent Liabilities
Long-term debt and lease obligation:   474 67 
Liabilities, other than long-term debt8331,2675,757   
Due to related parties 5,757   
Other liabilities      
Operating lease, liability8331,267474 67
Other undisclosed noncurrent liabilities  5,757    
Total noncurrent liabilities:8337,0246,231 67 
Total liabilities:27,22825,85921,5041,8673,4015,457
Equity
Equity, attributable to parent105,195158,378136,40643,05836,53558,667
Common stock222544
Additional paid in capital374,129361,689279,089189,604178,767177,622
Accumulated other comprehensive income (loss)27(115)    
Accumulated deficit(268,963)(203,198)(142,685)(146,551)(142,236)(118,959)
Total equity:105,195158,378136,40643,05836,53558,667
TOTAL LIABILITIES AND EQUITY:132,423184,237157,91044,92539,93764,123

Income Statement (P&L) ($ in thousands)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues24,35415,2161,12015,000 20,157
Cost of revenue(2,809)(1,335)(171)   
Cost of goods and services sold(2,809)(1,335)    
Provision for loan, lease, and other losses   (171)   
Gross profit:21,54513,88194915,000 20,157
Operating expenses(93,478)(76,562)(112,337)(21,357)(24,444)(31,339)
Other undisclosed operating income   171   
Operating loss:(71,933)(62,681)(111,217)(6,357)(24,444)(11,181)
Nonoperating income6,1682,1681,1292,0421,174785
Other nonoperating income6,1682,1681,1291,814  
Interest and debt expense(231)(230)196   
Loss from continuing operations before equity method investments, income taxes:(65,996)(60,743)(109,892)(4,315)(23,271)(10,397)
Other undisclosed income (loss) from continuing operations before income taxes231230(196)   
Loss from continuing operations before income taxes:(65,765)(60,513)(110,088)(4,315)(23,271)(10,397)
Income tax expense   (2)   
Loss from continuing operations:(65,765)(60,513)(110,090)(4,315)(23,271)(10,397)
Loss before gain (loss) on sale of properties:(110,090)(4,315)(23,271)(10,397)
Net loss:(65,765)(60,513)(110,090)(4,315)(23,271)(10,397)
Other undisclosed net income attributable to parent      
Net loss available to common stockholders, diluted:(65,765)(60,513)(110,090)(4,315)(23,271)(10,397)

Comprehensive Income ($ in thousands)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(65,765)(60,513)(110,090)(4,315)(23,271)(10,397)
Other comprehensive loss  (115)    
Comprehensive loss:(65,765)(60,628)(110,090)(4,315)(23,271)(10,397)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent142 (647)   
Comprehensive loss, net of tax, attributable to parent:(65,623)(60,628)(110,737)(4,315)(23,271)(10,397)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: